Generic Medicine Info
Indications and Dosage
Skin fungal infections
Adult: As 0.25% cream: Apply once daily for at least 2-3 weeks (up to 6 weeks for foot infections). Continue for 3-5 days after cure is attained.

Nail fungal infections
Adult: As 5% lacquer: Paint onto the affected nail 1-2 times weekly after filing and cleansing. Continue until nail has regenerated and the affected areas are cured. Treatment duration: Approx 6 months (fingernail) or 9-12 months (toenail).
Special Precautions
Childn. Pregnancy and lactation.
Adverse Reactions
Hypersensitivity reactions, skin irritation, erythema, pruritus, contact dermatitis, urticaria, blister. Rarely, burning sensation, severe skin reactions, nail disorder (e.g. nail discolouration, onychoclasis, onychorrhexis).
Patient Counseling Information
Avoid contact w/ eyes, ears, mucous membranes, and surrounding areas around the nail. Avoid using cosmetic lacquer or artificial nails.
Description: Amorolfine, a morpholine derivative, is highly active in vitro against numerous pathogenic and opportunistic fungi. It alters fungal cell membranes by interfering w/ sterol biosynthesis.
Absorption: Systemic absorption is neglible.
Distribution: Penetrates into and diffuses through the nail plate.
Store below 30°C. Protect from heat.
MIMS Class
Topical Antifungals & Antiparasites
ATC Classification
D01AE16 - amorolfine ; Belongs to the class of other antifungals for topical use.
Anon. Amorolfine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 20/09/2016.

Buckingham R (ed). Amorolfine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 20/09/2016.

Joint Formulary Committee. Amorolfine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 20/09/2016.

Loceryl 5% Nail Lacquer (Laboratoires Galderma). Taiwan FDA Ministry of Health and Welfare. Accessed 20/09/2016.

Loceryl Nail Lacquer 5% (Galderma Australia Pty Ltd). Medsafe. Accessed 20/09/2016.

Disclaimer: This information is independently developed by MIMS based on Amorolfine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Loceryl
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in